Dergiler / Türk Kardiyoloji Derneği Arşivi / 2020 / Cilt: 48 - Sayı: 7

COVID-19 ve RAAS blokerleri: Aliskiren uygun bir seçenek olabilir mi?

COVID-19 and RAAS blockers: Could Aliskiren be an appropriate option?

Sayfa
631–634
Yayın Tarihi
2022-11-06
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
🔖

Bu Makaleye Atıf Yap

ŞEN, S., ÜRESİN, A. Y. (2022). COVID-19 ve RAAS blokerleri: Aliskiren uygun bir seçenek olabilir mi?. Türk Kardiyoloji Derneği Arşivi, Cilt: 48 - Sayı: 7, 631–634. https://ajindex.com/articles/631987

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (4)

  1. WHO. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). Available at: https://www. who.int/docs/default-source/coronaviruse/who-china-jointmission- on-covid-19-final-report.pdf Accessed Feb 28, 2020
  2. Chen Y, Guo Y, Pan Y, Zhao ZJ. Structure analysis of the receptor binding of 2019-nCoV. Biochem Biophys Res Commun 2020;525:135−40. [CrossRef] 3. Gurwitz D. Angiotensin receptor blockers as tentative SARSCoV- 2 therapeutics. Drug Dev Res 2020;81:537−40. [CrossRef] 4. Kostenis E, Milligan G, Christopoulos A, Sanchez-Ferrer CF, Heringer-Walther S, Sexton PM, et al. G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation 2005;111:1806−13. [CrossRef] 5. Turner AJ, Hiscox JA, Hooper NM. ACE2: from vasopeptidase to SARS virus receptor. Trends Pharmacol Sci 2004;25:291−4. [CrossRef] 6. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol 2020;17:259−60. [CrossRef] 7. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med 2020;382:1653−59. [CrossRef] 8. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al; ESC Scientific Document Group. 2018 ESC/ ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018;39:3021−104. [CrossRef] 9. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin- converting enzyme 2 protects from severe acute lung failure. Nature 2005;436:112−6. [CrossRef] 10. Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med 2005;11:875−9
  3. Sen S, Ufuktepe B, Özünal ZG, Üresin Y. Renin inhibitors in diabetes and hypertension: an update. EXCLI J 2014;13:1111−9
  4. Mourad JJ, Levy BI. Interaction between RAAS inhibitors and ACE2 in the context of COVID-19. Nat Rev Cardiol 2020;17:313. [CrossRef] 13. Omar A. Molecular Docking Reveals the Potential of Aliskiren, Dipyridamole, Mopidamol, Rosuvastatin, Rolitetracycline and Metamizole to Inhibit COVID-19 Virus Main Protease. ChemRxiv. 2020 April 3. doi: https://doi.org/10.26434/chemrxiv. 12061302.v1. [Epub ahead of print]. [CrossRef] 14. Guo Y, Zeng J, Li Q, Li P, Luo FM, Zhang WZ, et al. Preliminary clinical study of direct renin inhibitor aliskiren in the treatment of severe COVID-19 patients with hypertension. [Article in Ch